Journal
ANTI-CANCER DRUGS
Volume 20, Issue 2, Pages 97-103Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CAD.0b013e328322fbc5
Keywords
FFC14A; KP1019; pharmacokinetics; phase I; ruthenium
Categories
Funding
- Faustus Forschungs Compagnie, Leipzig, Germany
Ask authors/readers for more resources
A phase I and pharmacokinetic study was carried out with the new ruthenium complex Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019, FFC14A). Seven patients with various types of solid tumours refractory to standard therapy were treated with escalating doses of KP1019 (25-600 mg) twice weekly for 3 weeks. No dose-limiting toxicity occurred. Ruthenium plasma concentration-time profiles after the first dose and under multiple-dose conditions were analysed using a compartmental approach. The pharmacokinetic disposition was characterised by a small volume of distribution, low clearance and long half-life. Only a small fraction of ruthenium was excreted renally. The area under the curve values increased proportionally with dose indicating linear pharmacokinetics. Anti-Cancer Drugs 20:97-103 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available